Betty M. Tijms

Jan 8, 2024 | nature.com | Betty M. Tijms |Henne Holstege |Lisa Vermunt |Niccolò Tesi |Eugeen Vanmechelen |Frederik Barkhof | +1 more

AbstractAlzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in cerebrospinal fluid, based on 1,058 proteins, with different levels in individuals with AD (n = 419) compared to controls (n = 187).

Sep 1, 2023 | nature.com | Betty M. Tijms

The treatment of Alzheimer disease has entered a new era, with a number of disease-modifying anti-amyloid-β therapies reaching the market in the past few years. Here we discuss the newest advances from phase III trials of solanezumab and donanemab. Refers to Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023); Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer’s disease. N. Engl. J. Med.